The 4F2hc/LAT1 complex transports l-DOPA across the blood–brain barrier

PROTEIN MEASUREMENT WITH THE FOLIN PHENOL REAGENT

Lowry, O. H., Rosebrough, N., Farr, A. L., & Randall, R. (1951) · Journal of Biological Chemistry · doi:10.1016/s0021-9258(19)52451-6 · Cited by 316,394

A pharmacokinetic analysis program (multi) for microcomputer.

Yamaoka, K., Tanigawara, Y., Nakagawa, T., & Uno, T. (1981) · Journal of Pharmacobio-Dynamics · doi:10.1248/bpb1978.4.879 · Cited by 2,451

Multidrug-resistance gene (P-glycoprotein) is expressed by endothelial cells at blood-brain barrier sites.

Cordon‐Cardo, C., O’Brien, J. P., Casals, D., Rittmann-Grauer, L., Biedler, J. L., Melamed, M. R., & Bertino, J. R. (1989) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.86.2.695 · Cited by 1,750

Astrocytes induce blood–brain barrier properties in endothelial cells

Janzer, R. C., & RAFF, M. C. (1987) · Nature · doi:10.1038/325253a0 · Cited by 1,613

Cloning and Expression of a Plasma Membrane Cystine/Glutamate Exchange Transporter Composed of Two Distinct Proteins

Sato, H., Tamba, M., Ishii, T., & Bannai, S. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.17.11455 · Cited by 1,111

Expression Cloning and Characterization of a Transporter for Large Neutral Amino Acids Activated by the Heavy Chain of 4F2 Antigen (CD98)

Kanai, Y., Segawa, H., Miyamoto, K., Uchino, H., Takeda, E., & Endou, H. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.37.23629 · Cited by 1,109

Amino-acid transport by heterodimers of 4F2hc/CD98 and members of a permease family

Mastroberardino, L., Spindler, B., Pfeiffer, R., Skelly, P. J., Loffing, J., Shoemaker, C. B., & Verrey, F. (1998) · Nature · doi:10.1038/26246 · Cited by 557

Identification and Functional Characterization of a Na+-independent Neutral Amino Acid Transporter with Broad Substrate Selectivity

Segawa, H., Fukasawa, Y., Miyamoto, K., Takeda, E., Endou, H., & Kanai, Y. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19745 · Cited by 499

Selective expression of the large neutral amino acid transporter at the blood–brain barrier

Boado, R. J., Li, J. Y., Nagaya, M., Zhang, C., & Pardridge, W. M. (1999) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.96.21.12079 · Cited by 482

Identification of a Membrane Protein, LAT-2, That Co-expresses with 4F2 Heavy Chain, an L-type Amino Acid Transport Activity with Broad Specificity for Small and Large Zwitterionic Amino Acids

Pineda, M., Fernández, E., Torrents, D., Estévez, R., López‐Iglesias, C., Camps, M., Lloberas, J., Zorzano, A., & Palacı́n, M. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.28.19738 · Cited by 407

Amino acid transporter LAT1 is expressed on cancer cell-derived exosomes with potential as a diagnostic and prognostic biomarker

Liu, Y., Ohgaki, R., Okanishi, H., Xu, M., & Kanai, Y. (2024) · Scientific Reports · doi:10.1038/s41598-024-79425-9 · Cited by 10

Compensatory neuritogenesis of serotonergic afferents within the striatum of a transgenic rat model of Parkinson’s disease

Stemick, J., Gauer, C., Wihan, J., Moceri, S., Xiang, W., von Hörsten, S., Kohl, Z., & Winkler, J. (2020) · Brain Research · doi:10.1016/j.brainres.2020.147119 · Cited by 9

Phenylalanine-Based AMPA Receptor Antagonist as the Anticonvulsant Agent with Neuroprotective Activity—In Vitro and In Vivo Studies

Latacz, G., Sałat, K., Furgała, A., Martyniak, A., Olejarz‐Maciej, A., Honkisz-Orzechowska, E., & Szymańska, E. (2022) · Molecules · doi:10.3390/molecules27030875 · Cited by 9

Crossing the Borders: the amino acid transporter LAT1 (SLC7A5) in the Blood-Brain Barrier

Scalise, M., Scanga, R., Console, L., Galluccio, M., Marzano, F., Magrì, A., Pochini, L., & Indiveri, C. (2025) · Neurochemistry International · doi:10.1016/j.neuint.2025.106070 · Cited by 10

Bile Duct Ligation Upregulates Expression and Function of L-Amino Acid Transporter 1 at Blood–Brain Barrier of Rats via Activation of Aryl Hydrocarbon Receptor by Bilirubin

Zheng, X., Yang, H., Qin, L. F., Wang, S., Xie, L., Lu, Y., Kong, W., Zhu, L., Liu, L., & Liu, X. (2021) · Biomedicines · doi:10.3390/biomedicines9101320 · Cited by 8

L-type Amino Acid Transporter 1 (SLC7A5)-Mediated Transport of Pregabalin at the Rat Blood-Spinal Cord Barrier and its Sensitivity to Plasma Branched-Chain Amino Acids

Akashi, T., Noguchi, S., Takahashi, Y., Nishimura, T., & Tomi, M. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2022.12.028 · Cited by 8

Imaging of cerebral tryptophan metabolism using 7-[18F]FTrp-PET in a unilateral Parkinsonian rat model

Endepols, H., Zlatopolskiy, B. D., Zischler, J., Alavinejad, N., Apetz, N., Vus, S., Drzezga, A. E., & Neumaier, B. (2021) · NeuroImage · doi:10.1016/j.neuroimage.2021.118842 · Cited by 8

The safety and tolerability of levodopa eye drops for the treatment of ocular disorders: A randomized first‐in‐human study

Thomson, K., Karouta, C., Sabeti, F., Anstice, N. S., Leung, M., Jong, T., Maddess, T., Morgan, I. G., Game, J., & Ashby, R. (2022) · Clinical and Translational Science · doi:10.1111/cts.13392 · Cited by 8

Assessment of treatment response by autoradiography with (14)C-aminocyclopentane carboxylic acid, (67)Ga-DTPA, and (18)F-FDG in a herpes simplex virus thymidine kinase/ganciclovir brain tumor model.

Miyagawa, T., Oku, T., Sasajima, T., Dasai, R., Beattie, B. J., Finn, R. D., Gelovani, J. G., & Blasberg, R. G. (2003) · PubMed · Cited by 8

Gold nanoparticles as scaffolds for poor water soluble and difficult to vehiculate antiparkinson codrugs

Crescenzo, A. D., Cacciatore, I., Petrini, M., D’Alessandro, M., Petragnani, N., Boccio, P. D., Profio, P. D., Boncompagni, S., Spoto, G., Türkez, H., et al. (2016) · Nanotechnology · doi:10.1088/1361-6528/28/2/025102 · Cited by 8

Carriership of the rs113883650/rs2287120 haplotype of the SLC7A5 (LAT1) gene increases the risk of obesity in infants with phenylketonuria

Bik-Multanowski, M., Madetko‐Talowska, A., Betka, I., Swieczka, E., Didycz, B., Orchel-Szastak, K., Bik-Multanowska, K., Starostecka, E., Jagłowska, J., Mozrzymas, R., et al. (2020) · Molecular Genetics and Metabolism Reports · doi:10.1016/j.ymgmr.2020.100640 · Cited by 8

Change in Cationic Amino Acid Transport System and Effect of Lysine Pretreatment on Inflammatory State in Amyotrophic Lateral Sclerosis Cell Model

Latif, S., & Kang, Y. (2021) · Biomolecules & Therapeutics · doi:10.4062/biomolther.2021.037 · Cited by 8

Modeling cryo-EM structures in alternative states with AlphaFold2-based models and density-guided simulations

Shugaeva, T. E., Howard, R. J., Haloi, N., & Lindahl, E. R. (2025) · Communications Chemistry · doi:10.1038/s42004-025-01751-4 · Cited by 14

Molecular Variability in Levodopa Absorption and Clinical Implications for the Management of Parkinson’s Disease

de Menezes, A. L. P., Bloem, B. R., Beckers, M., Piat, C., Benarroch, E. E., & Savica, R. (2024) · Journal of Parkinson s Disease · doi:10.3233/jpd-240036 · Cited by 7

In silico study of levodopa in hydrated lipid bilayers at the atomistic level

Megariotis, G., Romanos, N. A., Avramopoulos, A., Μικαελιάν, Γ., & Theodorou, D. N. (2021) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2021.107972 · Cited by 7

Dopamine

Gomes, P., & Soares-da-Silva, P. (2008) · doi:10.1002/9783527626236.ch11 · Cited by 7

Structural insights into the substrate transport mechanism of the amino acid transporter complex

Yang, H., Shi, T., Dong, J., Zhang, T., Li, Y., Guo, Y., Yuan, Y., Yang, L., Dong, J.-T., & Yan, R. (2025) · Journal of Biological Chemistry · doi:10.1016/j.jbc.2025.110569 · Cited by 6

Characterization of Aripiprazole Uptake Transporter in the Blood-Brain Barrier Model hCMEC/D3 Cells by Targeted siRNA Screening

Kadoguchi, M., Arakawa, H., Honda, R., Hotta, K., Shirasaka, Y., Deguchi, Y., & Tamai, I. (2022) · Pharmaceutical Research · doi:10.1007/s11095-022-03223-z · Cited by 6

A Comparative Study of Successful Central Nervous System Drugs Using Molecular Modeling

Kim, H. E., Sulaimon, S., Menezes, S., Son, A., & Menezes, W. J. C. (2011) · Journal of Chemical Education · doi:10.1021/ed100824u · Cited by 6

Uptake and Decarboxylation of l-3,4-Dihydroxyphenylalanine in Cultured Monkey Placenta Amniotic Epithelial Cells

Elwan, M. A., & Sakuragawa, N. (2006) · Placenta · doi:10.1016/j.placenta.2006.02.005 · Cited by 6

Small molecule, nanoparticle and liposomal strategies for LAT1-mediated chemotherapy delivery

Bullock, J. L., Gillette, D. D., & Smith, J. A. I. (2023) · Results in Chemistry · doi:10.1016/j.rechem.2023.101056 · Cited by 5

Investigating white matter alterations in Parkinson’s disease using multi-shell free-water DTI and NODDI: insights into neurodegeneration and levodopa effects

Bergamino, M., Zhu, S., Shill, H. A., & Stokes, A. M. (2025) · Frontiers in Neurology · doi:10.3389/fneur.2025.1605753 · Cited by 5

Erythroid SLC7A5/SLC3A2 amino acid carrier controls red blood cell size and maturation

Bouthelier, A., Fernández-Arroyo, L., Mesa-Ciller, C., Cibrian, D., Martín-Cófreces, N., Castillo-González, R., Calero, M., Herráez-Aguilar, D., Guajardo-Grence, A., Pacheco, A. M., et al. (2022) · iScience · doi:10.1016/j.isci.2022.105739 · Cited by 2

Molecular imaging with endogenous and exogenous ligands: The instance of antibodies, peptides, iodide and cupric ions

Duatti, A. (2014) · Nuclear Medicine and Biology · doi:10.1016/j.nucmedbio.2014.11.004 · Cited by 5

Amino Acid Transport Across the Blood—Brain Barrier

Smith, Q. R., Mandula, H., & Parepally, J. M. R. (2006) · Elsevier eBooks · doi:10.1016/b978-012369442-3/50200-2 · Cited by 5

Inhibition of brain glutamate carboxypeptidase II (GCPII) to enhance cognitive function

Wiseman, R., Bigos, K. L., Arnsten, A. F. T., & Slusher, B. S. (2024) · Advances in pharmacology · doi:10.1016/bs.apha.2024.10.018 · Cited by 4

Cloning and functional analysis of goat glucose transporter 4

Zhu, L., Yu, Q., Lin, J., Zhang, Q., & Yang, Q. (2013) · Molecular Biology Reports · doi:10.1007/s11033-013-2915-6 · Cited by 4

Dopaminergic Neurotransmission

Schetz, J. A., & Sibley, D. R. (2007) · doi:10.1002/9780470101001.hcn007 · Cited by 4

Increased sodium fluorescein transport by corticosteroids is inhibited by a LAT-1 specific inhibitor in retinal pigment epithelial cells in vitro

Misawa, N., & Honda, S. (2023) · Scientific Reports · doi:10.1038/s41598-023-50196-z · Cited by 3

Obstruction and Approaches to Cross the Drug Molecules through Blood Retinal Barrier: An Overview

Seethamraju, S. M., & Nori, L. P. (2024) · Pharmacophore · doi:10.51847/tblh98sxcq · Cited by 3

IFE.PTML: advancing neurotherapeutic nanoparticle release-system design for enhanced brain delivery

Ruiz-Escudero, A., Belii, M., Nader, K., Insausti, M., Castellanos-Rubio, I., Arrasate, S., Montemore, M. M., & González‐Díaz, H. (2025) · Machine Learning Science and Technology · doi:10.1088/2632-2153/ae038a · Cited by 3

Pichia pastoris and the Recombinant Human Heterodimeric Amino Acid Transporter 4F2hc-LAT1: From Clone Selection to Pure Protein

Kantipudi, S., Harder, D., Bonetti, S., Fotiadis, D., & Jeckelmann, J.-M. (2021) · Methods and Protocols · doi:10.3390/mps4030051 · Cited by 3

Prodrug Approaches for Central Nervous System Delivery

Smith, Q. R., & Lockman, P. R. (2010) · Methods and principles in medicinal chemistry · doi:10.1002/9783527633166.ch11 · Cited by 3

Adaptive cohort design and LAT1 expression scale: study protocol for a Phase 2a trial of QBS72S in breast cancer brain metastases

Taiwo, R., Harary, P. M., Trinh, T. T. H., Granucci, M., Bertrand, S., Carlson-Clarke, B., Chernikova, S. B., Therkelsen, K. E., Arora, M., Melisko, M., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14282-x · Cited by 2

Advances in the development of large neutral amino acid transporter 1 (LAT1) substrate analogues and inhibitors for the delivery of drugs and radiopharmaceuticals

Zhao, Y., Wang, Y., Shang, H., Xu, F., Gou, W., Hou, W., Wei, H., & Li, Y. (2025) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2025.118382 · Cited by 2

Disrupted transporter protein expression and cell-specific localization reveal neurovascular unit remodeling in human glioblastoma

Bao, X., Jiang, Y., Hermes, B., Sanai, N., & Li, J. (2026) · Neuro-Oncology Advances · doi:10.1093/noajnl/vdag070 · Cited by 2

Spatially resolved multiomics of human meningeal development reveal lineage and disease dynamics

To, K., Pett, J. P., Dufva, O., Chipampe, N.-J., Polański, K., Cujba, A.-M., Roberts, K., Predeus, A. V., Yayon, N., Kanemaru, K., et al. (2026) · Nature Cell Biology · doi:10.1038/s41556-026-02075-8 · Cited by 2

Targeting Circuit Abnormalities in Neurodegenerative Disease

Srinivasan, S. R. (2022) · Molecular Pharmacology · doi:10.1124/molpharm.122.000563 · Cited by 2

Strategies in Parkinson's Disease Therapeutics - A Need for Synergy of Ayurveda, Small Molecules and Nanoparticles aided Approaches

Choudhury, S., Garg, A., Anand, L., Bharath, M. M. S., Yadav, R., & Alladi, P. A. (2024) · Current Topics in Medicinal Chemistry · doi:10.2174/0115680266314877241105051752 · Cited by 2

Levodopa and nutrition support: A case report of Parkinsonism‐hyperpyrexia syndrome

Burslem, R., Ramos, L., Chou, C., Szlufman, C., & Ziegler, J. (2025) · Nutrition in Clinical Practice · doi:10.1002/ncp.11297 · Cited by 2

Molecular Mechanisms of the Inner Blood-Retinal Barrier Transporters

Tomi, M., & Hosoya, K. (2008) · Humana Press eBooks · doi:10.1007/978-1-59745-375-2_8 · Cited by 2

Applications of Nanotechnology/Nanomaterials in the Nervous System

Liu‐Snyder, P. (2007) · WORLD SCIENTIFIC eBooks · doi:10.1142/9789812779656_0005 · Cited by 2

Dopamine Synthesis by Non-Dopaminergic Neurons in the Stratium of Mice with and without Degeneration of the Nigrostriatal Dopaminergic System

Blokhin, V. E., Pronina, T. S., & Ugryumov, M. V. (2020) · Neurochemical Journal · doi:10.1134/s1819712420010043 · Cited by 2

Pharmacological Properties of Levodopa

Huot, P. (2014) · Springer eBooks · doi:10.1007/978-1-4471-6503-3_9 · Cited by 2

Transport of Protein and Antibody Therapeutics Across the Blood–Brain Barrier

Pardridge, W. M. (2015) · Wiley eBooks · doi:10.1002/9781118788523.ch8 · Cited by 2

Pharmacokinetics and Pharmacodynamics of Oxycodone and Morphine with Emphasis on Blood-Brain Barrier Transport

Boström, E. (2007) · KTH Publication Database DiVA (KTH Royal Institute of Technology) · Cited by 2

Transporter-Mediated Drug DeliveryPreprint

Gyimesi, G., & Hediger, M. A. (2022) · Preprints.org · doi:10.20944/preprints202211.0062.v1 · Cited by 1

Expressional prerequisites for targeted drug delivery to the pathological brain

Helgudóttir, S. S. (2021) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau424058297 · Cited by 1

Characterization of substrates and inhibitors of the human heterodimeric transporter 4F2hc-LAT1 using purified protein and the scintillation proximity radioligand binding assay

Kantipudi, S., Harder, D., & Fotiadis, D. (2023) · Frontiers in Physiology · doi:10.3389/fphys.2023.1148055 · Cited by 1

Ernährung bei der Parkinson-Krankheit

Ceballos-Baumann, A., & Fietzek, U. M. (2025) · Nervenheilkunde · doi:10.1055/a-2512-0254 · Cited by 1

Construction and Functional Evaluation of 2D and 3D Human Blood–Brain Barrier Models

Kurosawa, T., Kubo, Y., & Deguchi, Y. (2025) · Current human cell research and applications · doi:10.1007/978-981-97-9495-9_14 · Cited by 1

A strategy for improving blood−brain barrier permeability of ChE inhibitors through blood-brain barrier (BBB) transporter

Gao, Z., Hu, Y., Zheng, N., Wang, Q., Xie, C., Chen, M., Yeasrim, S., Wang, L., Zhang, T., Jia, Z., et al. (2026) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2026.118687 · Cited by 1

Gene delivery for cerebral neurodegenerative disorders: Current advancements and limitations

Dayma, K., & Upadhyay, A. (2026) · Molecular Therapy · doi:10.1016/j.ymthe.2026.06.030 · Cited by 1

Large Amino Acid‐Mimetic Peptide Redirects Exosomes to L‐Type Amino Acid Transporter 1 for Efficient miRNA Delivery and Cancer Suppression

Zhang, Y., Liu, R., Liang, S., Zhang, X., Hu, J. B., & Luo, X. (2026) · Small Structures · doi:10.1002/sstr.70559 · Cited by 1

Multi‐omics–driven precision medicine

Li, H., Zhao, Z., Zhang, Y., Ma, Y., Hu, G., Zeng, M., Yang, Z., Zhao, Z., Zhou, X., Hu, W., et al. (2026) · iMeta · doi:10.1002/imt2.70165 · Cited by 1

Cooperative synthesis of dopamine in the striatum of normal and parkinsonial mice

Kim, A., & Угрюмов, М. В. (2015) · Doklady Biochemistry and Biophysics · doi:10.1134/s1607672915010147 · Cited by 1

Role of transporters in drug distribution into the CNS

Ohtsuki, S. (2009) · Folia Pharmacologica Japonica · doi:10.1254/fpj.134.83 · Cited by 1

LAT1: A POTENTIAL CEREBROVASCULAR TARGET TO BREACH BBB

Dhanawat, M., Gupta, S., Das, R., & Mehta, D. K. (2022) · INDIAN DRUGS · doi:10.53879/id.59.03.12953 · Cited by 1

Case Report: 18F-Fluoro-L-Phenylalanine Positron Emission Tomography Findings and Immunoreactivity for L-Type Amino Acid Transporter 1 in a Dog With Meningioma

Lee, D., Yun, T., Kim, S., Koo, Y., Chae, Y., Kim, S., Chang, D., Yang, M., Kim, H., & Kang, B. (2022) · Frontiers in Veterinary Science · doi:10.3389/fvets.2022.899229 · Cited by 1

Médicaments radiopharmaceutiques : du diagnostic au théranostique des tumeurs neuroendocrines

Nicolas, L., Leclerc, P., Guilloteau, D., & Lebtahi, R. (2021) · Médecine Nucléaire · doi:10.1016/j.mednuc.2021.03.005 · Cited by 1

Blood–Brain Barrier Transport of an Essential Amino Acid After Cerebral Ischemia Reperfusion Injury

Suzuki, T., Miyazaki, Y., Ohmuro, A., Watanabe, M., Furuishi, T., Fukami, T., & Tomono, K. (2013) · Acta neurochirurgica. Supplementum · doi:10.1007/978-3-7091-1434-6_58 · Cited by 1

Amino acid transporters & amino acid metabolism in Trypanosoma brucei brucei.

Ebikeme, C. (2007) · Enlighten: Theses (The University of Glasgow) · Cited by 1

Investigating the mechanism by which the atypical antipsychotic clozapine reduces disease in experimental autoimmune encephalomyelitis

Zareie, P. (2017) · doi:10.26686/wgtn.17065139.v1 · Cited by 1

Drug Delivery in the Context of Stroke and Brain Trauma

Keep, R. F., Xiang, J., Zhou, N., & Andjelkovic, A. V. (2013) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-1-4614-9105-7_23

Étude de l'expression de LAT1 dans les métastases cérébrales

Papin-Michault, C. (2013) · HAL

Drug delivery system based on transport characteristics of biological membranes Molecular mechanisms of blood-brain barrier transport system and its contribution to drug delivery to the brain

Ohtsuki, S. (2006) · Drug Delivery System · doi:10.2745/dds.21.102

Physiological pharmacokinetics and membrane transport for drug delivery research

Terasaki, T., & Ohtsuki, S. (2005) · International Congress Series · doi:10.1016/j.ics.2005.06.070

Quantitative targeted absolute proteomics (QTAP)-based rational research on the human blood-brain barrier transport

Tachikawa, M., Uchida, Y., & Terasaki, T. (2013) · Drug Delivery System · doi:10.2745/dds.28.270

Energy and Mammalian Target of Rapamycin Complex 1 (mTORC1) in Minimal Change Nephrotic Syndrome

Yan, K. (2015) · Springer eBooks · doi:10.1007/978-4-431-55270-3_5

LAT1-mediated prodrug uptake: a way to breach the blood-brain barrier? "Designing high-affinity prodrugs capable of replacing endogenous substrates for LAT 1 at the blood-brain barrier can indeed result in an improved prodrug delivery to the brain."

Rautio, J. (2013)

Applications of Nanotechnology in Degenerative Disorders of the Brain

Khawaja, A. M., & Heiss, J. D. (2013) · CRC Press eBooks · doi:10.1201/b15274-33

Active Uptake System of L-DOPA in CNS

Sasaki, Y., Goshima, Y., & Misu, Y. (2005) · doi:10.1201/9781420023329-10

Moment-to-moment regulation of voltage-gated potassium channel function

Baronas, V. A. (2018) · cIRcle (University of British Columbia) · doi:10.14288/1.0368851

How to Apply Joint Estimated Tax Payments When Filing Separately: A Straightforward Answer to a Thorny Question

Laffie, L. S. (2004) · Journal of accountancy online/Journal of accountancy

SLC7A5 and neural development

Katada, T., & Sakurai, H. (2021) · Elsevier eBooks · doi:10.1016/b978-0-12-817986-4.00012-2

Blood–Brain Barrier Transporters and Central Nervous System Drug Response and Toxicity

Miller, D. W., Line, S., Safa, N. A., & Zhang, Y. (2021) · Wiley eBooks · doi:10.1002/9781119171003.ch12 · Cited by 1

Interplay between gut bacteria and Parkinson’s disease medication

van Kessel, S. P. (2021) · University of Groningen research database (University of Groningen / Centre for Information Technology) · doi:10.33612/diss.182831964

Active Uptake System of L-DOPA in CNS

Misu, Y., Goshima, Y., & Sasaki, Y. (2005) · CRC Press eBooks · doi:10.1201/9781420023329.ch3

Therapeutic Agents for Neurodegenerative Disorders

Merino, P. (2019) · doi:10.1002/9783527813421.ch10

Investigating the mechanism by which the atypical antipsychotic clozapine reduces disease in experimental autoimmune encephalomyelitis

Zareie, P. (2017) · Open Access Victoria University of Wellington | Te Herenga Waka (Figshare) · doi:10.26686/wgtn.17065139 · Cited by 1

Faculty Opinions recommendation of The L-type amino acid transporter LAT1 inhibits osteoclastogenesis and maintains bone homeostasis through the mTORC1 pathway.

Tanaka, S. (2019) · Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature · doi:10.3410/f.736165237.793562387

The Blood-Brain Barrier in Stroke and Trauma and How to Enhance Drug Delivery

Keep, R. F., Xiang, J., Zhou, N., & Andjelkovic, A. V. (2022) · AAPS advances in the pharmaceutical sciences series · doi:10.1007/978-3-030-88773-5_23

Blood-brain barrier-directed gene therapy as a strategy to treat Niemann-Pick type C2 disease

Rasmussen, C. L. M. (2022) · VBN Forskningsportal (Aalborg Universitet) · doi:10.54337/aau528833295

Transporter-Mediated Drug Delivery to the Brain

Puris, E., Gynther, M., & Fricker, G. (2024) · AAPS introductions in the pharmaceutical sciences · doi:10.1007/978-3-031-62604-3_1

Challenges of Brain Targeting and Mechanism of Drug Transfer Across Brain Barriers

Duarte, A. C., Mineiro, R., Santos, C. R. A., Costa, D. R. B., & Quintela, T. (2024) · Springer eBooks · doi:10.1007/978-981-97-2859-6_2

Applications of Nanotechnology in Degenerative Disorders of the Brain

Lopes, D. H. J., Sisi, F. Y., Mehrabian, A., Davoudkhani, M., Noroozıan, M., Khawaja, A. M., & Heiss, J. D. (2024) · Springer eBooks · doi:10.1007/978-3-030-80662-0_30

Developing Arterial Drugs: Lessons from the Hepatic Artery and Other Arterial Injections

Baig, A., Gamblin, T. C., Bello, R. J., & Joshi, S. (2025) · Springer eBooks · doi:10.1007/978-3-031-80173-0_12

Surgery‐induced inflammation reduces morphine distribution into cerebrospinal fluid

Wang, Y., Landry, K., Issa, M. E., Sleno, L., Julian, L. M., Hall, R., & Goralski, K. B. (2013) · The FASEB Journal · doi:10.1096/fasebj.27.1_supplement.668.2

Additional file 1 of Amino acid transporter LAT1 in tumor-associated vascular endothelium promotes angiogenesis by regulating cell proliferation and VEGF-A-dependent mTORC1 activation

Quan, L., Ohgaki, R., Hara, S., Okuda, S., Wei, L., Okanishi, H., Nagamori, S., Endou, H., & Kanai, Y. (2020) · Figshare · doi:10.6084/m9.figshare.13310272

Gabapentin CNS exposure and analgesic response are modulated by OCT2 genotype in patients with chronic neuropathic pain

Zhou, L., Yamamoto, P. A., Walker, M., Costa, A., Lauretti, G. R., Dach, F., Schmidt, S., & de Moraes, N. V. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1760901

A LAT1‐Compatible, Leadlike Tyrosine‐Naphthoquinone Conjugate With Anticancer Activity

Seymour, A., Peterson, C., Osafo, R., Ashimi, A. A., Williams, D., Echezabal, L. M., Carrier, C. C., Clarke, A., Padgett, C. W., Cerna, M. V. C. D., et al. (2026) · Drug Development Research · doi:10.1002/ddr.70269

Rôle des toxines urémiques et du facteur de transcription AhR dans la modulation de l'expression des transporteurs hépatiques au cours de l'insuffisance rénale chronique

Machado, T. S. (2017) · theses.fr (ABES) · doi:10.70675/2a78dabczf6daz4537z972az8bb38e1881ad

Sleep-wake regulation by Palladin via the blood-brain-barrier

Li, H. (2022) · theses.fr (ABES) · doi:10.70675/6142554dzdf7dz4640z8c76ze90c5609291d

CD98hc, une histoire au long cours(t)

Ibrahim, A. Y. (2023) · theses.fr (ABES) · doi:10.70675/4f8263c2za7cdz4fb6za204z666831bd12b6

Application of proteomics analysis to drug delivery system research

Inagaki, M., & Tachikawa, M. (2026) · Drug Delivery System · doi:10.2745/dds.41.65

Evaluation of drug absorption from oral dosage forms

Han, M., & Koziolek, M. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-34156-4.00023-6

Structure-guided targeting of the LAT1-4F2hc amino acid transporter in cancer and brain disorders

Hu, Z., Bröer, S., & Yan, R. (2026) · Medical Review · doi:10.1515/mr-2026-0046

Correlations between cerebrospinal fluid and plasma levels of GABA, glutamate, dopamine, and related metabolites, and their concentrations across neurological disorders

Deng, Y., Wu, W., Han, S., Jiang, H., & Guan, M. (2026) · Clinica Chimica Acta · doi:10.1016/j.cca.2026.121325

BindingDB Entry 50012563: LAT1 activity of carboxylic acid bioisosteres: Evaluation of hydroxamic acids as substrates.

BindingDB (2022) · UC San Diego · doi:10.7270/q22f7s4p

BindingDB Entry 50002808: Secondary carbamate linker can facilitate the sustained release of dopamine from brain-targeted prodrug.

BindingDB (2020) · UC San Diego · doi:10.7270/q2wm1h2c

Enzymic activity of the brain: microvessels vs. total forebrain homogenate

Djuričić, B. M., & Mruˇlja, B. B. (1977) · Brain Research · doi:10.1016/0006-8993(77)90694-1 · Cited by 65

Expression of a system L neutral amino acid transporter at the blood–brain barrier

Matsuo, H., Tsukada, S., Nakata, T., Chairoungdua, A., Kim, D. K., Ho, S., Inatomi, J., Yorifuji, H., Fukuda, J., Endou, H., et al. (2000) · Neuroreport · doi:10.1097/00001756-200011090-00021 · Cited by 147

SYNTHETIC AMINO ACIDS AND THE NATURE OF l ‐DOPA TRANSPORT AT THE BLOOD‐BRAIN BARRIER

Wade, L. A., & Katzman, R. (1975) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.1975.tb04415.x · Cited by 211

Blood-brain barrier and neuronal membrane transport of 6-[18F]fluoro-l-DOPA11Abbreviations: AAAD, aromatic l-amino acid decarboxylase; BBB, blood-brain barrier; BUI, brain uptake index; carbidopa, l-α-hydrazino-α-methyl-β-(3,4-dihydroxyphenyl)propionic acid; l-DOPA, l-3,4-dihydroxyphenylalanine; FDA, 6-fluorodopamine; [18F]FDOPA, 6-[18F]fluoro-l-3,4-dihydroxyphenylalanine; 4-[18F]FMT, 4-[18F]fluoro-l-meta-tyrosine; 6-[18F]FMT, 6-[18F]fluoro-l-meta-tyrosine; MeAIB, α-(methylamino)isobutyric acid; MPTP, 1-methyl-1,2,3,6-tetrahydropyridine; PD, Parkinson’s disease; PET, positron emission tomography; and PLP, pyridoxal phosphate.

Yee, R. E., Cheng, D. W., Huang, S.-C., Namavari, M., Satyamurthy, N., & Barrio, J. R. (2001) · Biochemical Pharmacology · doi:10.1016/s0006-2952(01)00787-0 · Cited by 35

Apical and basolateral 4F2hc and the amino acid exchange of L-DOPA in renal LLC-PK1 cells

Soares-da-Silva, P., & Serrão, P. (2005) · Amino Acids · doi:10.1007/s00726-005-0242-5 · Cited by 5